Recombinant PLAG1 Monoclonal Antibody (AN301944L)
For research use only.
| Verified Samples |
Verified Samples in WB: Human liver, Mouse liver, Rat liver Verified Samples in IHC: Human ovarian tumor |
| Dilution | WB 1:5000-1:10000, IHC 1:50 |
| Isotype | IgG, κ |
| Host | Rabbit |
| Reactivity | Human, Rat, Mouse |
| Applications | WB, IHC |
| Clonality | Monoclonal;Recombinant |
| Immunogen | Recombinant human PLAG1 fragment |
| Abbre | PLAG1 |
| Synonyms | ZNF, Zinc finger protein PLAG, Pleiomorphic adenoma gene, FGFR1/PLAG1 fusion variant, PLAG, COL1A2/PLAG1 fusion, FGFR1/PLAG1 fusion variant 3, Pleiomorphic adenoma gene 1, Pleiomorphic adenoma gene 1 protein, PSA, SGPA, Zinc finger protein PLAG1, ZNF912, PLAG1, PSA, SGPA |
| Swissprot | |
| Calculated MW | 56 kDa |
| Observed MW |
56 kDa
Western blotting is a method for detecting a certain protein in a complex sample based on the specific binding of antigen and antibody. Different proteins can be divided into bands based on different mobility rates. The mobility is affected by many factors, which may cause the observed band size to be inconsistent with the expected size. The common factors include: 1. Post-translational modifications: For example, modifications such as glycosylation, phosphorylation, methylation, and acetylation will increase the molecular weight of the protein. 2. Splicing variants: Different expression patterns of various mRNA splicing bodies may produce proteins of different sizes. 3. Post-translational cleavage: Many proteins are first synthesized into precursor proteins and then cleaved to form active forms, such as COL1A1. 4. Relative charge: the composition of amino acids (the proportion of charged amino acids and uncharged amino acids). 5. Formation of multimers: For example, in protein dimer, strong interactions between proteins can cause the bands to be larger. However, the use of reducing conditions can usually avoid the formation of multimers. If a protein in a sample has different modified forms at the same time, multiple bands may be detected on the membrane. |
| Cellular Localization | Nucleus |
| Concentration | 1 mg/mL |
| Buffer | PBS, 50% glycerol, 0.05% Proclin 300, 0.05% protein protectant. |
| Purification Method | Protein A purified |
| Research Areas | Epigenetics and Nuclear Signaling, Cancer |
| Clone No. | A660 |
| Conjugation | Unconjugated |
| Storage | Store at -20°C Valid for 12 months. Avoid freeze / thaw cycles. |
| Shipping | Ice bag |
| background | Pleiomorphic adenoma gene 1 protein (PLAG1) is a transcription factor whose activation results in up-regulation of target genes, such as IGFII, leading to uncontrolled cell proliferation. When PLAG1 overexpression in cultured cells, higher proliferation rate and transformation are observed. Other target genes such as CRLF1, CRABP2, CRIP2, PIGF are strongly induced in cells with PLAG1 induction. PLAG1 ectopic expression can trigger the development of pleomorphic adenomas of the salivary gland and lipoblastomas. PLAG1 overexpression is associated with up-regulation of IGFII, is frequently observed in hepatoblastoma, common primary liver tumor in childhood. PLAG1 cooperates with CBFB-MYH11, a fusion gene important for myeloid leukemia. |
Other Clones
{{antibodyDetailsPage.numTotal}} Results
-
{{item.title}}
Citations ({{item.publications_count}}) Manual MSDS
Cat.No.：{{item.cat}}
{{index}} {{goods_show_value}}
Other Formats
{{formatDetailsPage.numTotal}} Results
Unconjugated
-
{{item.title}}
Citations ({{item.publications_count}}) Manual MSDS
Cat.No.：{{item.cat}}
{{index}} {{goods_show_value}}
-
IF：{{item.impact}}
Journal：{{item.journal}} ({{item.year}})
DOI：{{item.doi}}Reactivity：{{item.species}}
Sample Type：{{item.organization}}
-
Q{{(FAQpage.currentPage - 1)*pageSize+index+1}}:{{item.name}}
